Categories: Health

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Zevra Therapeutics

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company’s new Chief Financial Officer pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

The Company granted Mr. Renz a new hire option to purchase 300,000 shares of Zevra’s common stock. The option has a 10-year term and an exercise price per share equal to $9.55, which was the closing price of Zevra’s common stock on March 18, 2026. The option vests over four years, subject to Mr. Renz’s continued service through the applicable vesting dates.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra’s vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com

GlobeNews Wire

Recent Posts

Maha Songkran World Water Festival 2026 opens in Bangkok

Five days of culture, music and water celebrations at Benchakitti Park reinforce UNESCO-recognised Songkran as…

6 hours ago

BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase…

16 hours ago

Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency

Los Angeles, CA, April 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational…

16 hours ago

Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management

SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF),…

20 hours ago

CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands

BEIJING, April 11, 2026 /PRNewswire/ -- CGTN published an article on the meeting between Xi…

20 hours ago